CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

Overview of attention for article published in Frontiers in immunology, July 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 10 X posts from 9 X users, with an upper bound of 40,268 followers.

RT @FrontImmunol: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond: Lisa A. King, Roeland L…

RT @FrontImmunol: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond: Lisa A. King, Roeland L…

RT @FrontImmunol: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond: Lisa A. King, Roeland L…

RT @FrontImmunol: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond: Lisa A. King, Roeland L…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.